About us
Our team
Our science
Radiopharmaceuticals
Our technology
Abstracts & publications
Our pipeline
News
All news
ASX releases
Media releases
Events and presentations
Investors
Share price
Annual reports
Shareholder newsletter
Analyst coverage
Corporate governance
Corporate policies
Contact us
About us
Our team
Our science
Radiopharmaceuticals
Our technology
Abstracts & publications
Our pipeline
News
All news
ASX releases
Media releases
Events and presentations
Investors
Share price
Shareholder newsletter
Analyst coverage
Corporate governance
Corporate policies
Contact us
Abstracts & publications
September 2022
LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity
Read more
Read more
October 2021
There is a world beyond αvβ3: Multimeric ligands for imaging of the integrin subtypes αvβ6, αvβ8,αvβ3 and α5β1 by positron emission tomography
Read more
Read more
June 2021
Preclinical development and characterisation of 99mTc-NM-01 for SPECT/CT imaging of human PD-L1
Read more
Read more
June 2021
European Molecular Imaging Meeting 2021 – 68-Trivehexin enables PET/CT imaging of carcinomas in humans by targeting the “cancer integrin” αvβ6
Read more
Read more
June 2021
European Molecular Imaging Meeting 2021 – Peptide trimers as complex systems: Optimization of pharmacokinetics by simple phenylalanine-tyrosine exchange
Read more
Read more
June 2021
PET/CT imaging of pancreatic carcinoma targeting the “cancer integrin” αvβ6
Read more
Read more
April 2021
PSA-targeted Alpha-, Beta-, and Positron emitting immunotheranostics in murine prostate cancer models and non human primates
Read more
Read more
February 2021
Radiotheranostic targeting of fPSA
Read more
Read more
Load more
Sign up to our mailing list.
Receive all the latest news from Radiopharm Theranostics.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form. Please fill out all starred fields.